摘要
目的:观察低分子肝素联合MVP方案治疗晚期非小细胞肺癌的短期疗效,毒副反应及对生存期的影响。方法:46例非小细胞肺癌随机分为两组,A组(治疗组)为MVP+肝素;B组(对照组)为单纯MVP。两组均接受MVP方案两周期。化疗方案:MMC 6 mg/m2,VDS 3 mg/m2×2,DDP 90 mg/m2。治疗组加用低分子肝素5 000u皮下注射,化疗前三天起,每日二次,共7天。结果:治疗组有效率56.5％(13/23),中位生存期12.1月(95％CI:8.52～14.64月),一年生存率52.2％。对照组有效率39.1％(9/23),中位生存期8.4月(95％CI:6.15-10.85月),一年生存率34.8％。治疗组中位生存期及一年生存率明显大于对照组(P<0.05)。主要毒副反应为Ⅱ-Ⅲ度血液毒性,消化道反应均为Ⅰ-Ⅱ度。两组间毒副反应比较无显著差异(P>0.05)。结论:低分子肝素联合MVP方案能提高NSCLC的化疗疗效,延长生存,不增加毒副反应。
Purpose: To evaluate the efficacy, safety and survival of low molecular weight heparin ( LMWH) plus chemotherapy in patients with advanced non-small cell lung cancer. Methods: 46 patients with NSCLC were randomized into chemotherapy plus LMWH. (study group) and chemotherapy only( control group). Both groups received two cycles of MVP regimen (MMC 6 mg/m2, YDS 3 mg/m2 x 2, DDP 90 mg/m2). Patients in the study group were treated with LMWH 5000u twice daily from the third day before chemtherapy up to 7 days. Results: The response rate was 56. 5% (13/23) for the study group and 39. l%(9/23) for the control group. Median survival time( MST) and 1-year survival rate were 12, 1 months(95%CI:8.52~14.64) and 52.2% for the study group compare 8.4 months(95%CI:6.15 ~ 10. 85) and 34. 8% for the control group. There were significant differences for MST( 12. 1 vs 8. 4) and 1 year survival rate(52. 2% vs 34. 8%) in the study group as compared to the control group. No difference in response rate and toxicities were found between the two groups. Conclusions: Chemotherapy( MVP regimen) plus LMWH is effective and safe. Prolonged survival was observed in patients who received MVP regimen plus LMWH.
出处
《中国癌症杂志》
CAS
CSCD
2003年第4期364-366,共3页
China Oncology
